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tions were 55.9 % stable angina or silent ischemia and 33.1% ACS. Risk factors were
well balanced between the 2 populations: hypertension (68.0% P vs. 68.6% X),
hypercholesterolemia (63.0% P vs. 63.4% X), diabetes (30.1% P vs. 28.1% X),
insulin-treated diabetes (7.8% P vs. 7.1% X), current smoking (22.0% P vs. 20.9% X).
Mean number of stents implanted per patient was 1.7 1.1. Procedural success was
very high in both groups: 97.6% in recipients of PROMUS Element stents and 97.8
% for XIENCE PRIME. At 30 days, clinical events were TVF 1.2% in P vs. 0.8% in
X (p¼0.56) including all death 0.6% in P vs.0.5% in X (p¼0.99), MI 0.7% in P vs.
0.5% in X (p¼0.74) and TVR 0.1 % in P vs. 0.1 in X (p¼0.85), Stent Thrombosis
(deﬁnite and probable) was 0.6% in P vs. 0.2% in X (p¼0.21).
Conclusions: Non inferiority in 30-day outcome was observed between the 2 stents;
the primary endpoint (12-month outcome) will be available for the meeting.
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Background: The incidence of LSD is unknown. The aims of this study were to
estimate the incidence of LSD associated with 4 commonly used DES platforms; to
compare the mechanism of LSD across platforms; to estimate the incidence of major
complications and assess angiographic procedural factors associated with LSD.
Methods: Angiographic and case details for 1,800 PCI cases were examined indi-
vidually by a panel 3 experienced interventional cardiologists. This cohort included
450 consecutive PCI procedures associated with the use of Promus Element, Xience
V, Biomatrix Flex and Resolute Integrity stents respectively. We classiﬁed cases as:
no LSD, LSD, and stent not visible. Cases of LSD were classiﬁed according to
mechanism (guide catheter or secondary device related). Treatment, subsequent
clinical outcome and cases in which re-entry of the stent following LSD was difﬁcult
were recorded.
Results: LSD was detected in a higher proportion with the Promus Element (3.1%)
compared to other platforms (Xience V 0.9%, Biomatrix 0.7%, Resolute 0.7%;
p¼0.002). Guide catheter related LSD occurred equally in all 4 platforms; Promus
Element 1.1%, Xience V 0.9%, Biomatrix 0.7%, Resolute 0.7%; p¼0.85. However, 9/
24 cases were caused by a secondary device, all of which occurred in the Promus
Element stent (p<0.0001). Stent thrombosis occurred in 1 of the 3 cases in which LSD
was not identiﬁed at the time of procedure. Difﬁculty re-entering the deformed stent
was encountered in 6 cases, all of which were in cases of secondary device impact on
Promus Element stents. Univariate predictors of LSD were previous CABG, culprit
vessel, ostial involvement and lesion tortuosity. Multivariate predictors of LSD were
the Promus Element stent, Guideliner use, post-dilation balloons and number of stents
deployed.
Conclusions: LSD is more common than previously reported.LSD in ostial lesions
caused by guide catheter or guide catheter extension occurred equally with all plat-
forms. LSD associated with secondary devices only occurred with the Element stent,
complicating >3% of procedures where it was frequently associated with difﬁculty re-
entering the deformed stent. However, no sequelae were detected when LSD was
recognised and treated.
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Background: Stent fracture (SF) is associated with restenosis and thrombosis. The
contemporary incidence and clinical implications of SF remain uncertain in view of
newer drug-eluting stents (DES). The FDA Manufacturer and User Facility Experi-
ence Database (MAUDE) is an electronic system that aims to capture voluntarily
reported device-related safety issues.
Methods: The MAUDE database was searched from January 2008 through March
2013 for “stent fractures” and “coronary fractures”. Data were extracted with respect
to types of DES, lesion characteristics, presence of overlapping DES, time from index
procedure to SF presentation, clinical presentation of SF, treatments and outcomes of
SF.B6 JACC Vol 62/18/Suppl B j October 27–NovembResults: A total of 126 patients were identiﬁed with coronary SF. The median time
from index procedure, when available, to SF was 17 months [IQR 6-33]. The majority
of patients with SF presented with chest pains and 15.1% had documented acute
coronary syndrome. Most of the SF occurred in lesions with at least moderate
tortuosity (66%) and calciﬁcations (70%). More than half (57.1%) of the reported SF
involved overlapping stents. The observed SF was 41.3% in the LAD, 40.5% in the
RCA, 9% in the LCX and 4% in the vein grafts. There were 29 overlapping stents in
the left anterior descending (LAD) artery (26.9%), 25 in RCA (23.2%) and 4 in LCX
(3.7%), respectively. SF was reported more frequently with Cypher (61.1%), followed
by Xience (16.7%), Promus (9.5%), Endeavor (5.6%), Taxus (4.8%) and BMS (2.4%).
Almost half of reported SF were treated with another DES (54%), 15% had balloon
angioplasty only, 7% underwent CABG, 5% had bare metal stent and another 5% with
medical therapy.
Conclusions: Throughout the DES platform evolution, there are continued SF re-
ported. However, Cypher remained the most commonly reported SF in the MAUDE
database. In accordance with previous reports, Cypher, LAD, RCA, moderate tortu-
osity and calciﬁcations, and overlapping stents were a recurrent observation seen
with SF.
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Background: Stent thrombosis (ST) remains a major concern in patients with acute
coronary syndromes (ACS) treated with drug-eluting stents (DES).
Methods: ADAPT-DES was a multicenter prospective study evaluating outcomes in
8,583 patients treated with DES, aspirin, and clopidogrel, and evaluated with platelet
reactivity testing. The frequency and consequences of 1-year ST (deﬁnite/probable)
were evaluated in the subset of 4,436 patients with ACS (STEMI [n¼813], NSTEMI
[n¼1,250], unstable angina [UA; n¼2,373]).
Results: ST within 1 year occurred in 50 patients (1.1%) and was associated with high
1-year rates of mortality (30.4%) and myocardial infarction (82.6%). ST occurred
more frequently in patients with PAD (2.3% vs 1.0%, p¼0.026), hypertension (1.4%
vs 0.4%, p¼0.008), STEMI vs NSTEMI/UA (1.9% vs 1.0%, p¼0.033), ejection
fraction 40% (2.4% vs 1.0%, p¼0.005), no intravascular ultrasound (IVUS)-
guidance (1.4% vs 0.8%, p¼0.049), stent size 3.0 mm (1.5% vs 0.8%, p¼0.049),
early versus later generation DES (1.5% vs 0.9%, p¼0.043), high platelet reactivity
post clopidogrel (PRU >208) (1.8% vs 0.6%, p<0.001), and premature dual anti-
platelet therapy (DAPT) discontinuation (4.6% vs 1.0%, p¼0.008). Independent
predictors of ST by Cox regression are shown in the Table.er 1, 2013 j TCT Abstracts/ORAL/Bare Metal and Drug-Eluting Stents
Interaction between diabetic status and lesion complexity for 1-year safety
and efﬁcacy outcomes
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Efﬁcacy
endpoints
TLR 4.6% 4.8% 0.96
(0.64,1.44
8.0% 4.5% 1.80
(1.39,2.33)
0.01
TVR 7.4% 6.8% 1.13
(0.81, 1.58)
10.6% 5.9% 1.81
(1.45, 2.27)
0.02
Safety
endpoints
Cardiac
dearh or MI
3.6% 2.1% 1.71 (1.00-
2;93)
5.7% 4.7% 1.22
(0.93,1.60)
0.28
Stent
Thrombosis
0.7% 0.3% 2.32 (0.60,
8.97)
1.7% 0.9% 1.87 (1.05,
3.32)
0.78
Independent Predictors of Stent Thrombosis at 1 Year
HR 95% CI p Value
Clinical variables
Hypertension 3.93 1.53 – 10.12 0.005
STEMI vs NSTEMI/
UA
2.72 1.46 – 5.06 0.002
History of
peripheral vascular
disease
2.18 1.05 – 4.51 0.040
Angiographic/
procedural
variables
Ejection fraction
40%
2.41 1.15 – 5.00 0.020
IVUS-guided
stenting
0.49 0.24 – 0.90 0.045
Later vs early
generation DES
0.54 0.29 – 1.00 0.050
Other variables
Premature DAPT
discontinuation
5.16 2.57 – 10.34 <0.001
VerifyNow P2Y12
PRU >208
2.92 1.57 – 5.42 <0.001
Separate Cox models were used for clinical, angiographic/procedural, and other variables
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SConclusions: ST within 1 year occurs inw1% of ACS patients treated with DES and
is associated with high rates of myocardial infarction and mortality. Strategies that
may reduce ST in ACS patients include the use of more potent ADP antagonists, better
strategies to achieve DAPT adherence, the use of later generation DES, and optimi-
zation of post-stent results with IVUS.
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Background: Previous studies have shown conﬂicting results in regard to efﬁcacy
outcomes of drug-eluting stents (DES) in patients with and without diabetes mellitus
(DM). Little is known on the impact of baseline lesion complexity on clinical
outcomes in these patients.
Methods: Patient-level data from 18 prospective randomized DES trials were pooled
(ACUITY; COMPARE; C-SIRIUS; ENDEAVOR 2; ENDEAVOR 3; ENDEAVOR
4; E-SIRIUS; HORIZONS-AMI; RAVEL; SIRIUS; SPIRIT 2; SPIRIT 3; SPIRIT 4;
TAXUS 1; TAXUS 2; TAXUS 4; TAXUS 5; TAXUS 6). Propensity-adjusted
outcomes according to the presence of DM and lesion complexity (ACC/AHA class
A/B1 vs. B2/C).
Results: Among 18,441 randomized patients, 3,467 (19%) had DM. Pts with vs.
without DM had higher 1-year rates of TLR (HR [95%CI] ¼ 1.34 [1.05, 1.70]), TVR
(HR [95%CI] ¼ 1.40 [1.15, 1.72]) and TVR non-TLR (HR [95%CI] ¼ 1.62 [1.14,
2.31). The 1-year rates of cardiac death or myocardial infarction (MI) were also higher
in DM (HR [95%CI] ¼ 1.40 [1.09, 1.81]). As shown in the Table, an interaction was
present between DM status and ACC/AHA lesion class on the need for repeat
revascularization after DES. There was no interaction between DM status and ACC/
AHA lesion class on safety endpoints.
Conclusions: In the DES era, the rates of TLR and TVR after PCI of non-complex
lesions are similar in DM and non-DM patients, whereas complex lesions still have
higher repeat revascularization rates if DM is present. Compared to non-DM, DM
patients continue to have higher rates of clinical restenosis in complex lesions, and of
cardiac death and MI in all patients. Despite advances in DES, new strategies are
needed for the diabetic patient.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-20
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Background: This article reports the 2-year clinical outcomes of the abluminal
groove-ﬁlled biodegradable polymer sirolimus-eluting stent (SES) FIREHAWK
(MicroPort Medical, Shanghai, China) compared with the everolimus-eluting stent
(EES) XIENCE V in the randomized TARGET I trial.
Methods: A total of 458 patients with single de novo native coronary lesions
<¼24 mm in length and a coronary artery >¼2.25 to <¼4.0 mm in diameter were
enrolled in the TARGET I study, a prospective, randomized, non-inferiority trial. The
primary endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. The
secondary endpoint, target lesion failure (TLF), was deﬁned as the composite of
cardiac death, target vessel myocardial infarction (TVMI), or ischemia-driven target
lesion revascularization (iTLR). Clinical follow-up was scheduled at 1-, 6- and 12-
month, and annually up to 5 years for all enrolled patients. All adverse clinical events
were adjudicated by an independent committee.
Results: The 9-month in-stent LLL of the FIREHAWK was comparable to the
XIENCE V group (0.130.24 mm vs. 0.130.18 mm, p¼0.94; difference and 95%
conﬁdence interval 0.00 [-0.04, 0.04] mm; p for non-inferiority <0.0001). After 2
years, the TLF rates were 2.7% and 2.6% in FIREHAWK and XIENCE V group,
respectively (p ¼ 0.97). Between 1 year and 2 years, only 1 new iTLR was occurred
in each group, with no additional cardiac death and TVMI. No deﬁnite / probable
stent thrombosis was observed in both groups at 2 years. The major results are shown
in the table.acts/ORAL/Bare Metal and Drug-Eluting Stents B7
